Showing results (161-170 of 241) with videos related to

Sort By:
Pageof 25
Molecular Pharmacology|June 16, 2017
<i>TCL1A</i> Single-Nucleotide Polymorphisms and Estrogen-Mediated Toll-Like Receptor-MYD88-Dependent Nuclear Factor-<i>κ</i>B Activation: Single-Nucleotide Polymorphism- and Selective Estrogen Receptor Modulator-Dependent Modification of Inflammation and Immune ResponseMing-Fen Ho, James N Ingle, Tim Bongartz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 1995
Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifenP E Goss, R M Clark, U Ambus, et al.
The Lancet. Oncology|May 30, 2014
Breast cancer in ChinaLei Fan, Kathrin Strasser-Weippl, Jun-Jie Li, et al.
Breast Cancer Research and Treatment|March 24, 2016
Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27Judith-Anne W Chapman, Lois E Shepherd, James N Ingle, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 30, 2018
<i>TCL1A</i>, a Novel Transcription Factor and a Coregulator of Nuclear Factor <i>κ</i>B p65: Single Nucleotide Polymorphism and Estrogen DependenceMing-Fen Ho, Edroaldo Lummertz da Rocha, Cheng Zhang, et al.
British Journal of Cancer|September 19, 2014
Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapyY Chavarri-Guerra, M J Higgins, J Szymonifka, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2005
The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)K M Wasan, P E Goss, P H Pritchard, et al.
Catheterization and Cardiovascular Diagnosis|February 1, 1989
Angina and vasospasm at rest in a patient with an anomalous left coronary systemG L Maddoux, J E Goss, B W Ramo, et al.
Nature Communications|November 4, 2021
Postpartum breast cancer has a distinct molecular profile that predicts poor outcomesSonali Jindal, Nathan D Pennock, Duanchen Sun, et al.
The Oncologist|August 13, 2008
Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?William R Miller, John Bartlett, Angela M H Brodie, et al.
Pageof 25